Bristol-Myers Squibb/$BMY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Ticker

$BMY

Primary listing

NYSE

Industry

Pharmaceuticals

Employees

34,100

ISIN

US1101221083

BMY Metrics

BasicAdvanced
$96B
17.61
$2.67
0.41
$2.44
5.27%

What the Analysts think about BMY

Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.

Bulls say / Bears say

Bristol Myers Squibb's recent partnership with BioNTech to co-develop the experimental cancer drug BNT327, involving a $1.5 billion upfront payment and potential for over $11 billion in total value, positions the company at the forefront of innovative oncology treatments. (reuters.com)
The U.S. approval and launch of Cobenfy, a novel treatment for schizophrenia, marks a significant expansion into the central nervous system therapeutic area, potentially opening new revenue streams. (biospace.com)
Bristol Myers Squibb's acquisition of Mirati Therapeutics for $4.8 billion, completed in January 2024, enhances its oncology pipeline with promising targeted therapies, potentially driving future growth. (wikipedia.org)
The company's forecasted 2025 revenue of $45.5 billion falls below Wall Street estimates, primarily due to increased generic competition for older drugs, leading to a nearly 4% drop in shares. (reuters.com)
Bristol Myers Squibb reported a net loss of $8.95 billion in 2024, a significant decline from a net income of $8.03 billion in 2023, largely due to substantial expenses related to recent acquisitions. (monexa.ai)
The loss of exclusivity for key cancer drugs like Revlimid, Pomalyst, Sprycel, and Abraxane is expected to result in a revenue decline of approximately 18-20% of the Legacy Portfolio in 2025. (1stoncology.com)
Data summarised monthly by Lightyear AI. Last updated on 24 Jun 2025.

BMY Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BMY Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BMY

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Jul3
Bristol-Myers Squibb
Dividend·Ex-dividend
Aug1
Bristol-Myers Squibb
Dividend·Payment
$0.62Per share
FAQs